LB1577. Outcomes of Pregnant Women Exposed to Sotrovimab for the Treatment of COVID-19 in the Omicron Predominant Era (PRESTO)

BACKGROUND: Sotrovimab, a monoclonal antibody with efficacy against SARS-CoV-2 including certain Omicron variants, has been used in treatment of mild-moderate COVID-19. Limited data exists regarding its use in pregnant women. METHODS: Electronic medical record review of pregnant COVID-19 patients tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Tuan, Jessica, Sharma, Manas, Kayani, Jehanzeb, Davis, Matthew W, McManus, Dayna, Topal, Jeffrey E, Ogbuagu, Onyema
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752459/
http://dx.doi.org/10.1093/ofid/ofac492.1887

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752459/
http://dx.doi.org/10.1093/ofid/ofac492.1887

Ejemplares similares